Feasibility study of the adjuvant chemoradiotherapy for the patients with high-risk rectal submucosal invasive cancer after the local resection - Feasibility study of the adjuvant chemoradiotherapy for the patients with high-risk rectal submucosal invasive cancer

One patient was ineligible. Twenty-three patients completed treatment, with a completion rate of 82% (80% confidence interval, 69-91%); the remaining five patients completed treatment with protocol deviation. The median relative dose intensity of capecitabine was 100% (range, 58-100%). Common adverse events included radiation dermatitis (54%), anal pain (39%) and anal mucositis (29%). No grade-3 or higher adverse events were reported.